Inhibition of cancer cells by Synthesit
Data from scientific work
The developers' guest, Marina Dukhinova, a candidate of Biological Sciences, Saint Petersburg.

Together with Vladislav Aleksandrovich Karabanov, the creator of Synthesit, Marina discussed the findings of the scientific work that established the outstanding anti-cancer activity of Synthesit with minimal toxic effect on healthy cells.

We invite you to read the text version of the conversation

Vladislav Karabanov: Is there anything similar to Synthesit in its effect in the actual result?

Marina Dukhinova: I think monodrugs, the drugs based on a single active compound with similar effects, at least I'm yet not aware of.
Vladislav Karabanov: Marina, thank you for coming, from Saint-Petersburg, it was a long way. In fact, we have people who follow our project, what effects Synthesit has on human health and, of course, your work, your report on the test results of Synthesit on cell models, it seems to be of great interest and you have carried out this work on tumor cell lines. In a nutshell, can you tell us what it is, please, not following the text, but your opinion?

Marina Dukhinova: Yes, of course, Vladislav. First of all, thank you very much for inviting me to Sochi and it's a great joy for me to have experience working with Synthesit as a potential medicine for, apparently, prevention and treatment for chronic diseases in the future. As you noticed, we have chosen tumor cell lines, because, of course, the problem of cancer remains one of the acute problems in the current healthcare system. We have picked, perhaps one of the most common forms - the bowel cancer and the lung cancer. Needless to say, that patients with these diseases need constant treatment, and it was interesting to see how Synthesit influences the tumor cells and the normal human cells. To our surprise, to our pleasant surprise, we found out that Synthesit is able to kill tumor cells with a fairly high efficiency. At the same time, it is completely safe for human cells - for healthy human cells, that basically gives us a huge opportunity for further testing, further study of this product. And of course, the first question arose what is the basis of its effect...
Vladislav Karabanov: The mechanism, yes.

Marina Dukhinova: What is the mechanism of action. Since Synthesit is an iron-based product, first of all, and cancer cells, tumor cells are the cells that are accustomed to live in a low oxygen environment, low nutrient environment and this is the basis of the main adaptation processes, the main changes that distinguish them from normal cells. Of course, it is reasonable to assume that it is the oxidative stress, generation of active oxygen forms itself can be an important mechanism of action of Synthesit. Moreover, this oxidative stress specifically affects tumor cells, but it does not occur in normal human cells.
Vladislav Karabanov: We have discussed this issue together before the video recording. It should be understood that the tumor cells they, basically, develop and in general the tumor progression appears as a result of hypoxia, that is, lack of oxygen, lack of oxygen.

Marina Dukhinova: Hypoxia is an unavoidable consequence of the formation of a tumor: the larger the tumor grows under the condition of what at the current stages of medical development, we are unlikely to be able to detect a tumor at the early stages of its development, as a rule, we see already quite large neoplasms and in these tumors, of course, hypoxia is always observed, especially in the central part of the tumor where it's quite difficult for oxygen to reach, as well as for nutrients, and for the medicine, which always impedes the treatment against this tumor. We always see adaptability to the low oxygen environment.
Vladislav Karabanov: The tumor develops at a low oxygen level.

Marina Dukhinova: Exactly.
Vladislav Karabanov: Thus Synthesit activates the hematopoietic system, activates the oxygen transportation and thus, it creates a tumor suppressive environment, and thereby they are like dying, while there practically was no impact on healthy cells.

Marina Dukhinova: We don't know yet how Synthesit works exactly, here is one of the hypotheses, as you fairly noted, that the blood supply may improve as well as the oxygen supply to the tumor cells, that definitely deteriorates their viability, that is the key stress factor for their existence. At the same time, apparently, the iron itself can act in this case as a toxic agent for tumor cells and it causes the generation of active oxygen forms, makes tumor cells to actually kill themselves.
Vladislav Karabanov: We can already say that, well, let's say, before treatment with Synthesit, while it is too early to state yet, but as a preventive measure, this is basically already the case...

Marina Dukhinova: Well, as a preventive measure - this is definitely can be justified. We need to run further tests, of course, to find out how exactly this system works, why do we observe such a positive effect in our in vitro models.
Vladislav Karabanov: You told us that you had carried out experiments with nanostructures, nanomaterials, and nano-microelements, and the result was, well, completely different. People keep asking: Perhaps you need to check simple iron or is there a difference?

Marina Dukhinova: In terms of nanomaterials, they slightly differ in their activity. The fact is, they're not that specific, I would say not very specific compared to Synthesit. They are likely to kill both healthy cells and tumor cells, and this is an important problem of modern nano-therapeutic approaches. No doubt there are a number of ways to combine nanotherapy with other approaches that involve more specific delivery of nanoparticles to the tumor area, and in this case, the treatment is justified. But the systematic use of nanoparticles is still out of the question, at least in the treatment for cancer, because it is very unsafe for a patient.
Vladislav Karabanov: Yes, because they - nanoparticles, they also kill healthy cells.

Marina Dukhinova: They can.
Vladislav Karabanov: They can kill healthy cells. While Synthesit is safe for healthy cells. Well, also, I introduced you to the findings that show the increase in the number of platelets, this was tested on monkeys - experimental monkeys. To be honest, since I'm not a medical doctor or a biologist, we are basically engaged in physics and chemistry. Your understanding, what is the reason of that increase in the number of platelets, and it is known that Synthesit improves blood fluidity, at the same time.

Marina Dukhinova: Actually, it's a very interesting observation. I am very glad that I was able to learn about these results and draw some preliminary conclusions. The fact is that platelets deliver important growth factors. The growth factors that promote regeneration for example, blood vessel regeneration and regeneration of the central nervous system. Of course, within the norm, platelets can not get into the brain, but if we are talking about people with pre-stroke, with stroke conditions, where the isolation of the central nervous system from blood is disrupted and platelets start to get in the brain too, and if this flow is stimulated by Synthesit, it may be a positive factor. At the same time, some experts will object to me here that this may be a risk factor as well, a factor of thrombosis, but at the same time, as you have noticed, we are observing improvements in blood fluidity and reduced risk of blood clots.
Vladislav Karabanov: You have conducted various experiments with different materials, preparations, substances with these cell models. Is there anything similar in effect to Synthesit in the actual result?

Marina Dukhinova: I think monodrugs, the drugs based on a single active compound with similar effect, at least I'm yet not aware of, because, as a rule, anyway when we begin to begin to work in the field of anti-cancer therapy all, all medicines that we initially test, as a rule, have a toxic effect on healthy cells and in this regard, Synthesit favorably differs from those that I had the opportunity to study that is definitely a favorable factor for patients. At the same time, you can overcome this by using a combination of some substances, but in this case we are talking about Synthesit as a monodrug, and again, it facilitates the way to obtain the substance, and some side risks.
Vladislav Karabanov: The research will continue. I hope that we will cooperate with Marina. Thank you very much, Marina. I think we will also record, report, and talk about our achievements. Thanks!

Marina Dukhinova: Thank you for the invitation. Of course, we will continue to work, and we want to realize the full potential of Synthesit, having other experimental systems, I think, about it we will tell later on.
You can study and download the scientific research at this link

Join our socials
Join our socials
Other articles on the subject:
Dietary supplements

Privacy policy

OOO "NIC Synthestech", INN/KPP: 2320250187 / 236701001
Corporate Address: Kurortny prospekt 73, Sochi, 354002, Russia
Russian-Swiss production